Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 4/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1735354 | 1.00 | OPRM1 (0.42) | OPRM1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1734403 | 1.00 | OPRM1 (0.42) | OPRM1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3766620 | 1.00 | OPRM1 (0.42) | OPRM1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL410055 | 0.77 | OPRM1 (0.44) | OPRM1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL31124279 | 0.77 | OPRM1 (0.44) | OPRM1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL24821526 | 0.74 | OPRM1 (0.44) | OPRM1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL599175 | 0.74 | KDM1A (0.47) | OPRM1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL599176 | 0.74 | KDM1A (0.47) | OPRM1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL12713048 | 0.74 | KDM1A (0.47) | OPRM1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL22052004 | 0.74 | OPRM1 (0.42) | OPRM1GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759584-B2 | Synthesis of biguanidines and triazines, and biguanidino-aluminium complexes as intermediates | BAYER CROPSCIENCE AG (DE) | 2014-06-24 | — | — | US | disclosed |
| EP-2231679-B1 | SYNTHESIS OF BIGUANIDINES AND TRIAZINES, AND BIGUANIDINO-ALUMINIUM COMPLEXES AS INTERMEDIATES | BAYER CROPSCIENCE AG (DE) | 2011-11-16 | — | — | EP | disclosed |
| US-20100305317-A1 | SYNTHESIS OF BIGUANIDINES AND TRIAZINES, AND BIGUANIDINO-ALUMINIUM COMPLEXES AS INTERMEDIATES | BAYER CROPSCIENCE AG (DE) | 2010-12-02 | — | — | US | disclosed |
| EP-2070934-A1 | Synthesis of biguanidines and triazines, and biguanidino-aluminium complexes as intermediates | Bayer CropScience AG (DE) | 2009-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305317-A1 | SYNTHESIS OF BIGUANIDINES AND TRIAZINES, AND BIGUANIDINO-ALUMINIUM COMPLEXES AS INTERMEDIATES | ATIC, SRM, F12 | OPRM1 2689/4885GRIN2D 1598/4885GRIN3B 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.